

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

OMB APPROVAL	
OMB Number:	3235-0080
Expires:	December 31, 2014
Estimated average burden hours per response:	1.7

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION  
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number [000-17082](#)

Issuer: <a href="#">NOVELION THERAPEUTICS INC.</a>
Exchange: <a href="#">The Nasdaq Stock Market LLC</a>

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address: <a href="#">887 Great Northern Way</a> <a href="#">Vancouver BRITISH COLUMBIA, CANADA V5T 4T5</a>
Telephone number: <a href="#">847-472-6700</a>

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

<a href="#">Common Stock</a>
------------------------------

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

- 17 CFR 240.12d2-2(a)(1)
- 17 CFR 240.12d2-2(a)(2)
- 17 CFR 240.12d2-2(a)(3)
- 17 CFR 240.12d2-2(a)(4)
- Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. <sup>1</sup>
- Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, [The Nasdaq Stock Market LLC](#) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

<input type="text" value="2019-12-17"/>	By	<input type="text" value="Aravind Menon"/>	<input type="text" value="Hearings Advisor"/>
Date		Name	Title

<sup>1</sup> Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. [See](#) General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Delisting Determination, The Nasdaq Stock Market, LLC, December 17, 2019, Novelion Therapeutics Inc. The Nasdaq Stock Market LLC (the Exchange) has determined to remove from listing the common stock of Novelion Therapeutics Inc. (the Company), effective at the opening of the trading session on December 27, 2019. Based on review of information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Listing Rule 5250(c)(1). The Company was notified of the Staff determination on August 21, 2019. The Company appealed the determination to a Hearing Panel. Upon review of the information provided by the Company, the Panel issued a decision dated October 7, 2019, denying the Company continued listing and notified the Company that trading in the Company securities would be suspended on October 9, 2019. The Company did not request a review of the Panel decision by the Nasdaq Listing and Hearing Review Council. The Listing Council did not call the matter for review. The Panel Determination to delist the Company became final on November 21, 2019.